Network meta-analysis
Acute pancreatitis
Overweight or obesity without diabetes (adults)
longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)
18
Randomized trials
14
Treatments
24,746
Participants
51
Events
In plain language
Across 18 trials with 24,746 participants, 0 of 13 treatments had a clearly better result than placebo on acute pancreatitis, and for 13 the evidence could not tell them apart from placebo. The most favorable estimate was for bimasema sc: hazard ratio (from event counts) 0.25 (95% credible interval 0.03 to 2.05).
- Bimasema sc: not convincingly different from placebo (certainty pending).
- Cagrilintide: not convincingly different from placebo (certainty pending).
- Standard care or no added treatment: not convincingly different from placebo (certainty pending).
- Mazdutide injection: not convincingly different from placebo (certainty pending).
- HRS-7535 tablet: not convincingly different from placebo (certainty pending).
- Loti po: not convincingly different from placebo (certainty pending).
- Efpeglenatide injection: not convincingly different from placebo (certainty pending).
- Vk2735 sc: not convincingly different from placebo (certainty pending).
- Semaglutide injection: not convincingly different from placebo (certainty pending).
- Semaglutide tablet: not convincingly different from placebo (certainty pending).
- Bimagrumab: not convincingly different from placebo (certainty pending).
- Liraglutide injection: not convincingly different from placebo (certainty pending).
- Tirzepatide injection: not convincingly different from placebo (certainty pending).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Hazard ratio (from event counts). Lower values favor the treatment.
| Treatment | Bayesian HR (95% CrI) | 95% prediction interval | Frequentist HR (95% CI) | Verdict | Confidence |
|---|---|---|---|---|---|
| Bimasema sc BIMASEMA_SC | 0.25 (0.03 to 2.05) | 0.02 to 2.65 | Unclear | pending | |
| Cagrilintide OTHER_ACTIVE_cagrilintide | 0.32 (0.03 to 3.44) | 0.02 to 4.27 | Unclear | pending | |
| Standard care or no added treatment STANDARD_CARE | 0.44 (0.03 to 5.00) | 0.03 to 6.08 | Unclear | pending | |
| Mazdutide injection MAZD_SC | 0.49 (0.03 to 6.39) | 0.03 to 7.74 | Unclear | pending | |
| HRS-7535 tablet HRS7535_PO | 0.63 (0.04 to 9.59) | 0.03 to 11.44 | Unclear | pending | |
| Loti po LOTI_PO | 0.63 (0.04 to 9.90) | 0.04 to 11.58 | Unclear | pending | |
| Efpeglenatide injection EFPE_SC | 0.64 (0.04 to 10.19) | 0.03 to 11.98 | Unclear | pending | |
| Vk2735 sc VK2735_SC | 0.66 (0.04 to 9.97) | 0.03 to 12.49 | Unclear | pending | |
| Semaglutide injection SEMA_SC | 0.85 (0.36 to 2.20) | 0.24 to 3.70 | Unclear | pending | |
| Semaglutide tablet SEMA_PO | 0.88 (0.05 to 14.24) | 0.04 to 16.87 | Unclear | pending | |
| Bimagrumab OTHER_ACTIVE_bimagrumab | 0.93 (0.11 to 6.36) | 0.09 to 8.05 | Unclear | pending | |
| Liraglutide injection LIRA_SC | 1.04 (0.12 to 7.79) | 0.10 to 9.78 | Unclear | pending | |
| Tirzepatide injection TIRZ_SC | 2.00 (0.30 to 14.46) | 0.24 to 19.10 | Unclear | pending |
Confidence in the results
How much each comparison can be trusted, rated with CINeMA in six domains and summarized with GRADE.
| Comparison | Within study bias | Reporting bias | Indirectness | Imprecision | Heterogeneity | Incoherence | Confidence |
|---|---|---|---|---|---|---|---|
| Bimasema sc versus Placebo | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Placebo | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Placebo | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Placebo | pending | some | pending | major | none | none | pending |
| Loti po versus Placebo | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Placebo | pending | some | pending | major | none | none | pending |
| Bimagrumab versus Placebo | pending | some | pending | major | none | none | pending |
| Cagrilintide versus Placebo | pending | some | pending | major | none | none | pending |
| Semaglutide tablet versus Placebo | pending | some | pending | major | none | none | pending |
| Semaglutide injection versus Placebo | pending | some | pending | major | none | none | pending |
| Standard care or no added treatment versus Placebo | pending | some | pending | major | none | none | pending |
| Tirzepatide injection versus Placebo | pending | some | pending | major | none | none | pending |
| Vk2735 sc versus Placebo | pending | some | pending | major | none | none | pending |
Every other comparison (78)
| Comparison | Within study bias | Reporting bias | Indirectness | Imprecision | Heterogeneity | Incoherence | Confidence |
|---|---|---|---|---|---|---|---|
| Bimasema sc versus Efpeglenatide injection | pending | some | pending | major | none | none | pending |
| Bimasema sc versus HRS-7535 tablet | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus HRS-7535 tablet | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Liraglutide injection | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Liraglutide injection | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Liraglutide injection | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Loti po | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Loti po | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Loti po | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Loti po | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Mazdutide injection | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Mazdutide injection | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Mazdutide injection | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Mazdutide injection | pending | some | pending | major | none | none | pending |
| Loti po versus Mazdutide injection | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Bimagrumab | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Bimagrumab | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Bimagrumab | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Bimagrumab | pending | some | pending | major | none | none | pending |
| Loti po versus Bimagrumab | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Bimagrumab | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Cagrilintide | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Cagrilintide | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Cagrilintide | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Cagrilintide | pending | some | pending | major | none | none | pending |
| Loti po versus Cagrilintide | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Cagrilintide | pending | some | pending | major | none | none | pending |
| Bimagrumab versus Cagrilintide | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| Loti po versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| Bimagrumab versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| Cagrilintide versus Semaglutide tablet | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Loti po versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Bimagrumab versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Cagrilintide versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Semaglutide tablet versus Semaglutide injection | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Loti po versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Bimagrumab versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Cagrilintide versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Semaglutide tablet versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Semaglutide injection versus Standard care or no added treatment | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Loti po versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Bimagrumab versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Cagrilintide versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Semaglutide tablet versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Semaglutide injection versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Standard care or no added treatment versus Tirzepatide injection | pending | some | pending | major | none | none | pending |
| Bimasema sc versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Efpeglenatide injection versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| HRS-7535 tablet versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Liraglutide injection versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Loti po versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Mazdutide injection versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Bimagrumab versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Cagrilintide versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Semaglutide tablet versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Semaglutide injection versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Standard care or no added treatment versus Vk2735 sc | pending | some | pending | major | none | none | pending |
| Tirzepatide injection versus Vk2735 sc | pending | some | pending | major | none | none | pending |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
Rank probabilities
| Treatment | Rank 1 | Rank 2 | Rank 3 | Rank 4 | Rank 5 | Rank 6 | Rank 7 | Rank 8 | Rank 9 | Rank 10 | Rank 11 | Rank 12 | Rank 13 | Rank 14 | Mean rank |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIMASEMA_SC | 19% | 18% | 15% | 12% | 9% | 7% | 5% | 4% | 3% | 3% | 2% | 2% | 1% | 4.2 | |
| OTHER_ACTIVE_cagrilintide | 16% | 14% | 13% | 11% | 9% | 7% | 6% | 4% | 4% | 4% | 4% | 4% | 3% | 2% | 5.1 |
| STANDARD_CARE | 11% | 11% | 11% | 10% | 9% | 8% | 7% | 5% | 5% | 5% | 5% | 5% | 5% | 3% | 6.1 |
| MAZD_SC | 10% | 10% | 10% | 9% | 9% | 8% | 7% | 5% | 5% | 5% | 6% | 6% | 6% | 5% | 6.5 |
| HRS7535_PO | 8% | 8% | 8% | 8% | 8% | 7% | 7% | 6% | 5% | 5% | 6% | 7% | 7% | 9% | 7.2 |
| LOTI_PO | 8% | 8% | 8% | 8% | 8% | 7% | 6% | 5% | 5% | 6% | 6% | 7% | 8% | 8% | 7.2 |
| EFPE_SC | 8% | 9% | 8% | 8% | 8% | 7% | 6% | 6% | 5% | 5% | 6% | 7% | 8% | 9% | 7.3 |
| VK2735_SC | 8% | 8% | 8% | 8% | 8% | 7% | 6% | 6% | 5% | 6% | 6% | 7% | 8% | 9% | 7.3 |
| SEMA_PO | 6% | 6% | 7% | 7% | 7% | 7% | 6% | 5% | 5% | 6% | 7% | 9% | 10% | 13% | 8.2 |
| SEMA_SC | 1% | 4% | 7% | 11% | 14% | 16% | 15% | 13% | 9% | 6% | 3% | 1% | 8.3 | ||
| OTHER_ACTIVE_bimagrumab | 2% | 4% | 5% | 7% | 7% | 8% | 8% | 7% | 8% | 9% | 9% | 10% | 9% | 7% | 8.5 |
| LIRA_SC | 2% | 3% | 5% | 6% | 7% | 7% | 7% | 7% | 7% | 8% | 10% | 11% | 11% | 9% | 8.8 |
| PLACEBO | 1% | 4% | 11% | 18% | 23% | 21% | 13% | 6% | 1% | 9.1 | |||||
| TIRZ_SC | 1% | 1% | 2% | 3% | 4% | 5% | 5% | 5% | 7% | 10% | 15% | 19% | 24% | 11.1 |
League table
Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | BIMASEMA_SC | OTHER_ACTIVE_cagrilintide | STANDARD_CARE | MAZD_SC | HRS7535_PO | LOTI_PO | EFPE_SC | VK2735_SC | SEMA_SC | SEMA_PO | OTHER_ACTIVE_bimagrumab | LIRA_SC | TIRZ_SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 4.01 0.49 to 39.81 | 3.17 0.29 to 36.87 | 2.26 0.20 to 29.63 | 2.03 0.16 to 28.67 | 1.59 0.10 to 25.71 | 1.58 0.10 to 23.38 | 1.56 0.10 to 26.73 | 1.52 0.10 to 24.11 | 1.17 0.45 to 2.79 | 1.14 0.07 to 19.57 | 1.07 0.16 to 9.47 | 0.96 0.13 to 8.24 | 0.50 0.07 to 3.30 |
| BIMASEMA_SC | 0.25 0.03 to 2.05 | BIMASEMA_SC | 0.80 0.03 to 17.88 | 0.55 0.02 to 13.98 | 0.50 0.02 to 14.23 | 0.38 0.01 to 12.87 | 0.38 0.01 to 12.74 | 0.38 0.01 to 12.21 | 0.37 0.01 to 14.59 | 0.29 0.03 to 2.55 | 0.28 0.01 to 10.06 | 0.28 0.02 to 4.14 | 0.24 0.01 to 4.95 | 0.12 0.01 to 2.11 |
| OTHER_ACTIVE_cagrilintide | 0.32 0.03 to 3.44 | 1.25 0.06 to 35.24 | OTHER_ACTIVE_cagrilintide | 0.72 0.02 to 24.77 | 0.63 0.02 to 21.24 | 0.49 0.01 to 20.06 | 0.49 0.01 to 18.83 | 0.50 0.01 to 18.27 | 0.49 0.01 to 18.67 | 0.37 0.03 to 4.84 | 0.35 0.01 to 16.87 | 0.35 0.02 to 8.78 | 0.31 0.02 to 5.84 | 0.16 0.01 to 3.49 |
| STANDARD_CARE | 0.44 0.03 to 5.00 | 1.80 0.07 to 47.31 | 1.39 0.04 to 42.00 | STANDARD_CARE | 0.90 0.02 to 31.47 | 0.71 0.02 to 27.86 | 0.70 0.02 to 27.17 | 0.68 0.02 to 26.94 | 0.69 0.02 to 24.83 | 0.52 0.03 to 6.65 | 0.50 0.01 to 20.77 | 0.48 0.02 to 12.91 | 0.44 0.02 to 11.07 | 0.23 0.01 to 2.91 |
| MAZD_SC | 0.49 0.03 to 6.39 | 1.99 0.07 to 58.69 | 1.58 0.05 to 50.61 | 1.12 0.03 to 40.58 | MAZD_SC | 0.79 0.02 to 34.07 | 0.80 0.02 to 33.32 | 0.77 0.02 to 34.66 | 0.76 0.02 to 32.68 | 0.57 0.03 to 8.71 | 0.57 0.01 to 26.08 | 0.55 0.02 to 13.58 | 0.49 0.02 to 13.44 | 0.24 0.01 to 5.78 |
| HRS7535_PO | 0.63 0.04 to 9.59 | 2.60 0.08 to 104 | 2.03 0.05 to 75.47 | 1.40 0.04 to 60.03 | 1.26 0.03 to 58.97 | HRS7535_PO | 1.01 0.02 to 46.80 | 0.98 0.02 to 52.45 | 0.97 0.02 to 47.82 | 0.72 0.04 to 12.73 | 0.69 0.02 to 36.85 | 0.69 0.02 to 21.64 | 0.62 0.02 to 18.69 | 0.30 0.01 to 8.88 |
| LOTI_PO | 0.63 0.04 to 9.90 | 2.64 0.08 to 94.63 | 2.04 0.05 to 76.61 | 1.44 0.04 to 59.88 | 1.26 0.03 to 61.35 | 0.99 0.02 to 48.20 | LOTI_PO | 1.00 0.02 to 52.99 | 0.99 0.02 to 45.70 | 0.74 0.04 to 12.64 | 0.71 0.02 to 36.48 | 0.70 0.03 to 22.33 | 0.63 0.02 to 19.36 | 0.31 0.01 to 9.11 |
| EFPE_SC | 0.64 0.04 to 10.19 | 2.60 0.08 to 89.93 | 1.99 0.05 to 77.72 | 1.47 0.04 to 58.76 | 1.30 0.03 to 53.41 | 1.02 0.02 to 46.32 | 1.00 0.02 to 49.42 | EFPE_SC | 1.02 0.02 to 49.83 | 0.74 0.04 to 14.13 | 0.73 0.01 to 42.60 | 0.70 0.03 to 22.52 | 0.62 0.02 to 21.64 | 0.32 0.01 to 8.89 |
| VK2735_SC | 0.66 0.04 to 9.97 | 2.69 0.07 to 89.31 | 2.06 0.05 to 82.44 | 1.45 0.04 to 61.22 | 1.32 0.03 to 51.03 | 1.03 0.02 to 55.49 | 1.01 0.02 to 48.43 | 0.98 0.02 to 55.38 | VK2735_SC | 0.77 0.04 to 13.31 | 0.74 0.01 to 38.23 | 0.74 0.02 to 24.67 | 0.66 0.02 to 19.16 | 0.32 0.01 to 8.91 |
| SEMA_SC | 0.85 0.36 to 2.20 | 3.41 0.39 to 37.08 | 2.74 0.21 to 36.08 | 1.93 0.15 to 29.02 | 1.76 0.11 to 28.87 | 1.38 0.08 to 25.82 | 1.35 0.08 to 22.63 | 1.35 0.07 to 24.43 | 1.30 0.08 to 25.14 | SEMA_SC | 0.97 0.06 to 19.46 | 0.93 0.13 to 9.08 | 0.84 0.10 to 8.62 | 0.43 0.05 to 3.53 |
| SEMA_PO | 0.88 0.05 to 14.24 | 3.63 0.10 to 132 | 2.84 0.06 to 118 | 1.98 0.05 to 90.25 | 1.75 0.04 to 75.85 | 1.44 0.03 to 65.57 | 1.40 0.03 to 59.18 | 1.37 0.02 to 71.53 | 1.35 0.03 to 69.95 | 1.03 0.05 to 18.06 | SEMA_PO | 0.98 0.03 to 28.49 | 0.88 0.03 to 29.92 | 0.43 0.01 to 12.43 |
| OTHER_ACTIVE_bimagrumab | 0.93 0.11 to 6.36 | 3.56 0.24 to 65.99 | 2.88 0.11 to 63.28 | 2.07 0.08 to 49.14 | 1.81 0.07 to 48.71 | 1.44 0.05 to 44.83 | 1.43 0.04 to 38.76 | 1.42 0.04 to 39.45 | 1.36 0.04 to 46.11 | 1.07 0.11 to 7.84 | 1.02 0.04 to 34.31 | OTHER_ACTIVE_bimagrumab | 0.89 0.05 to 15.27 | 0.45 0.02 to 7.25 |
| LIRA_SC | 1.04 0.12 to 7.79 | 4.13 0.20 to 86.44 | 3.25 0.17 to 59.98 | 2.30 0.09 to 59.57 | 2.04 0.07 to 58.96 | 1.60 0.05 to 47.97 | 1.58 0.05 to 46.49 | 1.61 0.05 to 49.41 | 1.52 0.05 to 44.42 | 1.19 0.12 to 10.42 | 1.13 0.03 to 37.49 | 1.12 0.07 to 20.57 | LIRA_SC | 0.50 0.03 to 8.04 |
| TIRZ_SC | 2.00 0.30 to 14.46 | 8.06 0.47 to 173 | 6.33 0.29 to 148 | 4.42 0.34 to 94.50 | 4.12 0.17 to 112 | 3.33 0.11 to 96.68 | 3.17 0.11 to 90.93 | 3.16 0.11 to 96.31 | 3.11 0.11 to 90.21 | 2.35 0.28 to 20.53 | 2.31 0.08 to 73.78 | 2.22 0.14 to 41.83 | 2.01 0.12 to 34.07 | TIRZ_SC |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- NoteOutcome assessment, time point: selected time points span 16.1 to 240 weeks
- NoteOutcome assessment, analysis set: mixed: full_analysis 1, randomized 1, safety 16
- NoteOutcome assessment, definition: mixed: acute kidney failure, prespecified MedDRA query 1, deaths 1, investigator reported pancreatitis 1, not stated 14, serious adverse events 1
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 17, while_on_treatment 1
- NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 17, treatment_policy 1
- NoteRisk of bias, blinding: mixed: double_blind 15, open_label 2, single_blind 1
- NoteRisk of bias, funding: mixed: industry 17, mixed 1
- NoteData handling, input conversions: arms_combined 13, printed_denominator 4
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TOGETHER-PsO | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2024 | adults; moderate to severe plaque psoriasis; PASI 12 or more; BMI 30 or more, or 27 to 30 with comorbidity |
| NCT02717858 | 16.1 | safety | serious adverse events | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2016 | age 18 to 64, BMI 27 or more, no diabetes, no gallbladder disease |
| STEP 1 | 75 | safety | not stated | not stated | not stated | not stated | while_on_treatment | treatment_policy | double_blind | industry | 2018 | adults; BMI 30 or more, or 27 or more with a weight related condition; no diabetes; HbA1c below 6.5 percent |
| SURMOUNT-OSA | 56 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | adults; AHI 15 or more; BMI 30 or more (27 in Japan); no diabetes |
| STEP 5 | 111 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent |
| NCT05579977 | 28 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes |
| BARIOPTIMISE | 28 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2018 | adults at least 1 year after RYGB or sleeve gastrectomy with 20 percent or less weight loss and suboptimal GLP-1 response |
| SCALE™ IBT | 58 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2017 | age 18 or older; BMI 30 or more; no diabetes; HbA1c below 6.5 percent; stable weight |
| VENTURE | 19 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | age over 18; BMI 30 or more, or 27 or more with comorbidity; BMI 50 or less; no diabetes |
| NCT05616013 | 48 | safety | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2022 | adults 18 to 80; BMI 30 or more, or 27 or more with comorbidity; no diabetes (HbA1c below 6.5 percent); weight below 150 kg |
| SELECT | 240 | full_analysis | acute kidney failure, prespecified MedDRA query | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | age 45 or older; BMI 27 or higher; established CVD; no diabetes; HbA1c below 6.5 percent |
| NCT02075281 | 26 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 64 years; BMI 30 to 42, or 27 to 30 with comorbidity; FPG below 7 mmol/L; HbA1c 6.5 percent or less; no diabetes |
| NCT04904913 | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | Chinese adults 18 to 75; BMI 28 or more, or 24 or more with comorbidity or hyperphagia; no diabetes, HbA1c below 6.5 |
| NCT03856047 | 26 | safety | investigator reported pancreatitis | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or more, or 27 or more with hypertension or dyslipidemia; no diabetes |
| NCT05623839 | 27 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 70; BMI 27 to 50; HbA1c below 6.5 percent; no diabetes |
| TOGETHER-PsA | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | single_blind | industry | 2024 | age 18 to 80; active psoriatic arthritis; BMI 30 or more, or 27 to 30 with a weight related comorbidity |
| NCT06250946 | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2024 | age 18 to 65; BMI 28 to 40; no diabetes, HbA1c below 6.5 percent |
| NCT01557166 | 34 | safety | deaths | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2012 | age 18 to 64; BMI 30 or more; AHI 15 or more; no diabetes; unable or unwilling to use CPAP |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| TOGETHER-PsO | A1 | STANDARD_CARE | 36 | arm, events | 0 / 134 | printed_denominator | R0014237:Table 3 | ||
| TOGETHER-PsO | A2 | TIRZ_SC | 36 | arm, events | 1 / 138 | printed_denominator | R0014237:Table 3 | ||
| NCT02717858 | A1 | LIRA_SC | 16.1 | arm, events | 0 / 26 | R0024932:Results | |||
| NCT02717858 | A2 | PLACEBO | 16.1 | arm, events | 0 / 26 | R0024932:Results | |||
| STEP 1 | A1 | SEMA_SC | 75 | arm, events | 3 / 1,306 | R0023399:Table 3 | |||
| STEP 1 | A2 | PLACEBO | 75 | arm, events | 0 / 655 | R0023399:Table 3 | |||
| SURMOUNT-OSA | A1+A3 | TIRZ_SC | 56 | arm, events | 2 / 234 | arms_combined | R0018977:Table 4 | ||
| SURMOUNT-OSA | A2+A4 | PLACEBO | 56 | arm, events | 0 / 235 | arms_combined | R0018977:Table 4 | ||
| STEP 5 | A1 | SEMA_SC | 111 | arm, events | 0 / 152 | R0021896:Table 3 | |||
| STEP 5 | A2 | PLACEBO | 111 | arm, events | 0 / 152 | R0021896:Table 3 | |||
| NCT05579977 | A1+A8 | PLACEBO | 28 | arm, events | 0 / 139 | arms_combined | R0004106:Results | ||
| NCT05579977 | A10+A11+A12+A13+A2+A3+A4+A5+A6+A9 | LOTI_PO | 28 | arm, events | 0 / 690 | arms_combined | R0004106:Results | ||
| NCT05579977 | A7 | SEMA_PO | 28 | arm, events | 0 / 73 | R0004106:Results | |||
| BARIOPTIMISE | A1 | PLACEBO | 28 | arm, events | 0 / 35 | R0017334:Results | |||
| BARIOPTIMISE | A2 | LIRA_SC | 28 | arm, events | 0 / 35 | R0017334:Results | |||
| SCALE™ IBT | A1 | LIRA_SC | 58 | arm, events | 0 / 142 | R0024012:Results | |||
| SCALE™ IBT | A2 | PLACEBO | 58 | arm, events | 0 / 140 | R0024012:Results | |||
| VENTURE | A1 | PLACEBO | 19 | arm, events | 0 / 35 | R0011224:Table 3 | |||
| VENTURE | A2+A3+A4+A5 | VK2735_SC | 19 | arm, events | 0 / 141 | arms_combined | R0011224:Table 3 | ||
| NCT05616013 | A1 | PLACEBO | 48 | arm, events | 1 / 56 | R0015266:Table 3 | |||
| NCT05616013 | A2+A3 | OTHER_ACTIVE_bimagrumab | 48 | arm, events | 1 / 113 | arms_combined | R0015266:Table 3 | ||
| NCT05616013 | A4+A5 | SEMA_SC | 48 | arm, events | 1 / 113 | arms_combined | R0015266:Table 3 | ||
| NCT05616013 | A6+A7+A8+A9 | BIMASEMA_SC | 48 | arm, events | 0 / 225 | arms_combined | R0015266:Table 3 | ||
| SELECT | A1 | SEMA_SC | 240 | arm, events | 17 / 8,803 | R0008068:Table 4 | |||
| SELECT | A2 | PLACEBO | 240 | arm, events | 24 / 8,801 | R0008068:Table 4 | |||
| NCT02075281 | A1 | PLACEBO | 26 | arm, events | 0 / 60 | R0011218:Results | |||
| NCT02075281 | A2+A3+A4+A5 | EFPE_SC | 26 | arm, events | 0 / 237 | arms_combined | R0011218:Results | ||
| NCT04904913 | A1+A2+A3 | MAZD_SC | 36 | arm, events | 0 / 186 | arms_combined | R0016107:Results | ||
| NCT04904913 | A4 | PLACEBO | 36 | arm, events | 0 / 62 | R0016107:Results | |||
| NCT03856047 | A1+A2+A3+A4+A5 | OTHER_ACTIVE_cagrilintide | 26 | arm, events | 0 / 506 | arms_combined | R0017871:Results | ||
| NCT03856047 | A6 | LIRA_SC | 26 | arm, events | 1 / 99 | R0017871:Results | |||
| NCT03856047 | A7 | PLACEBO | 26 | arm, events | 0 / 101 | R0017871:Results | |||
| NCT05623839 | A1 | PLACEBO | 27 | arm, events | 0 / 8 | R0013210:Supplement Table S2 | |||
| NCT05623839 | A2+A3 | MAZD_SC | 27 | arm, events | 0 / 24 | arms_combined | R0013210:Supplement Table S2 | ||
| TOGETHER-PsA | A1 | STANDARD_CARE | 36 | arm, events | 0 / 132 | printed_denominator | R0018951:Table 3 | ||
| TOGETHER-PsA | A2 | TIRZ_SC | 36 | arm, events | 0 / 138 | printed_denominator | R0018951:Table 3 | ||
| NCT06250946 | A1 | PLACEBO | 36 | arm, events | 0 / 46 | R0001289:Table 6 | |||
| NCT06250946 | A2+A3+A4+A5 | HRS7535_PO | 36 | arm, events | 0 / 189 | arms_combined | R0001289:Table 6 | ||
| NCT01557166 | A1 | LIRA_SC | 34 | arm, events | 0 / 180 | R0026203:Results | |||
| NCT01557166 | A2 | PLACEBO | 34 | arm, events | 0 / 179 | R0026203:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.